Tags

Type your tag names separated by a space and hit enter

Patent foramen ovale: where are we in 2009?
Am J Ther. 2009 Nov-Dec; 16(6):562-72.AJ

Abstract

Patent Foramen Ovale (PFO) is present in 20 - 25% of the population, and is known to be associated with a number of clinical syndromes. However, it is less clear that there is a causal (or contributory) role for the PFO in the development of thromboembolic stroke, systemic thromboembolization, decompression illness in divers, hypoxemia with obstructive sleep apnea, or migraine headaches. On-going and new randomized prospective trials are testing these relationships and are attempting to prove therapeutic benefit to closing the defects. This paper will review the existing literature on PFO, and will attempt to clarify some of the outstanding clinical management issues.

Authors+Show Affiliations

Columbia University Medical Center, New York, NY, USA. rs2463@columbia.edu

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19417592

Citation

Sommer, Robert J.. "Patent Foramen Ovale: Where Are We in 2009?" American Journal of Therapeutics, vol. 16, no. 6, 2009, pp. 562-72.
Sommer RJ. Patent foramen ovale: where are we in 2009? Am J Ther. 2009;16(6):562-72.
Sommer, R. J. (2009). Patent foramen ovale: where are we in 2009? American Journal of Therapeutics, 16(6), 562-72. https://doi.org/10.1097/MJT.0b013e318197eaef
Sommer RJ. Patent Foramen Ovale: Where Are We in 2009. Am J Ther. 2009 Nov-Dec;16(6):562-72. PubMed PMID: 19417592.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Patent foramen ovale: where are we in 2009? A1 - Sommer,Robert J, PY - 2009/5/7/entrez PY - 2009/5/7/pubmed PY - 2010/2/25/medline SP - 562 EP - 72 JF - American journal of therapeutics JO - Am J Ther VL - 16 IS - 6 N2 - Patent Foramen Ovale (PFO) is present in 20 - 25% of the population, and is known to be associated with a number of clinical syndromes. However, it is less clear that there is a causal (or contributory) role for the PFO in the development of thromboembolic stroke, systemic thromboembolization, decompression illness in divers, hypoxemia with obstructive sleep apnea, or migraine headaches. On-going and new randomized prospective trials are testing these relationships and are attempting to prove therapeutic benefit to closing the defects. This paper will review the existing literature on PFO, and will attempt to clarify some of the outstanding clinical management issues. SN - 1536-3686 UR - https://www.unboundmedicine.com/medline/citation/19417592/Patent_foramen_ovale:_where_are_we_in_2009 L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=19417592.ui DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.